Bronchiectasis definition

Bronchiectasis means a condition characterized by permanent dilation of the bronchi, which can result in recurrent respiratory infections, a disabling cough, shortness of breath, and hemoptysis (coughing up blood). The condition may be triggered by chronic respiratory infections and the associated inflammatory response.
View Source
Bronchiectasis means a diseased state defined by localised, irreversible dilation of part of the bronchial tree caused by destruction of the muscle and elastic tissue.
View Source
Bronchiectasis means a specific lung disease characterized by permanent dilatation of one or more bronchi. Patients with bronchiectasis often manifest clinical symptoms of chronic cough and sputum production and may experience recurrent chest infections.
View Source

Examples of Bronchiectasis in a sentence

  • If no additional milestones are agreed to within such time period, and the lack of milestones is not mutually agreed by both parties, then at PARI’s option, PARI may by providing prompt written notice to Transave, (i) make the license granted to Transave under this Agreement non-exclusive and PARI’s non-compete obligations set forth in Section 4.2 shall terminate or (ii) terminate the license granted to Transave under this Agreement, in each case solely with respect to Bronchiectasis.

  • If such milestone is still not met within twelve (12) months of the applicable time period, other than any failure resulting from a breach of this Agreement by PARI, then, subject to the provisions of Section 7.3, PARI shall have the option to terminate the license granted to Transave under this Agreement with respect to Bronchiectasis only by providing written notice thereof to Transave.

  • Subject to Section 4.2(b) below and the AKITA Rights, during the Term of this Agreement, PARI agrees that it and its Affiliates shall not compete with Transave (x) in CF and/or Bronchiectasis with a Competing Nebulizer in the Transave Field, within the Transave Territory, or (y) otherwise engage in the research, development, manufacture and/or commercialization of amikacin for pulmonary administration using a Competing Nebulizer.

  • During the Royalty Term, Transave shall pay to PARI an Annual Minimum Royalty in US dollars in accordance with Section 9.3 below; provided, however, that, in the event Transave has permanently discontinued to Exploit the Drug Product for CF in accordance with Section 7.1(a), then the Annual Minimum Royalty shall no longer be applicable for the Drug Product for CF but the obligation to pay Annual Minimum Royalties for the Drug Product for Bronchiectasis shall remain in effect.

  • The Performance Condition is satisfied only if the press release announcing top line results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis (“Press Release”) is issued on or before June 30, 2024 or such other later date as is determined by the Board or the Committee (such date, the “Press Release Deadline”).

  • If Transave fails to meet a milestone within the applicable time period, other than any failure resulting from a breach of this Agreement by PARI, then, subject to the provisions of Section 7.3, PARI shall have the option to render Transave's license hereunder non-exclusive solely with respect to Bronchiectasis and to terminate its obligation not to compete with Transave in Bronchiectasis as set forth in Section 4.2 of this Agreement.

  • Bronchiectasis is a cause of obstruction so when we say obstruction we mean the air does not come out of your lungs as rapidly as it should.

  • Hospital contact: University Hospitals of Derby & ▇▇▇▇▇▇ Respiratory consultant/nurse via switchboard:01332 340131 Specialist nurses: Asthma Team: 01332 787221 ▇▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇@▇▇▇.▇▇▇ IMPACT Team (COPD): 01332 788225 ▇▇▇▇.▇▇▇▇▇▇-▇▇▇▇@▇▇▇.▇▇▇ Bronchiectasis/ Respiratory Infection Team: 01332787159 ▇▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇@▇▇▇.▇▇▇ Chesterfield Royal Hospital Foundation Trust Respiratory consultant via switchboard: 01246 277271 ii.

  • If Transave fails to meet a milestone within the applicable time period, other than any failure resulting from a breach of this Agreement by PARI, then, subject to the provisions of Section 7.3, PARI shall have the option to render Transave’s license hereunder non-exclusive solely with respect to Bronchiectasis and to terminate its obligation not to compete with Transave in Bronchiectasis as set forth in Section 4.2 of this Agreement.

  • Bronchiectasis Subsequent follow-up at 6 and 12 months should determine whether benefit is being derived from therapy using objective measures, such as the exacerbation rate, quality of life as measured by a validated assessment tool, such as SGRQ.